Information  X 
Enter a valid email address

Physiomics PLC (PYC)

  Print   

Wednesday 15 September, 2021

Physiomics PLC

Notice of Results and Investor Presentation

RNS Number : 7728L
Physiomics PLC
15 September 2021
 

15 September 2021

 

Physiomics plc

("Physiomics") or ("the Company")

 

Notice of Results and Investor Presentation

 

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it will publish its results for the full year ending 30 June 2021 on Thursday, 30 September.

 

Dr Jim Millen, CEO of Physiomics, will provide a live presentation relating to the Company's full year results via the Investor Meet Company platform on 30 September at 2pm BST. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your the 'Investor Meet Company' dashboard up until 9:00 a.m. the day before the meeting or at any time during the live presentation.

 

Investors who already follow Physiomics plc on the Investor Meet Company platform will automatically be invited.  Potential investors can sign up to 'Investor Meet Company' for free and register to join the presentation via https://www.investormeetcompany.com/physiomics-plc/register-investor .

 

 

 

Enquiries:

 

Physiomics plc 

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORFZGMLVDVGMZM

a d v e r t i s e m e n t